SE8203161L - Sett att framstella 1,5-disubstituerade hydantoinanaloger - Google Patents

Sett att framstella 1,5-disubstituerade hydantoinanaloger

Info

Publication number
SE8203161L
SE8203161L SE8203161A SE8203161A SE8203161L SE 8203161 L SE8203161 L SE 8203161L SE 8203161 A SE8203161 A SE 8203161A SE 8203161 A SE8203161 A SE 8203161A SE 8203161 L SE8203161 L SE 8203161L
Authority
SE
Sweden
Prior art keywords
substituted
alkyl
group
hydroxy
carbon atoms
Prior art date
Application number
SE8203161A
Other languages
English (en)
Inventor
A G Caldwell
N Whittaker
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of SE8203161L publication Critical patent/SE8203161L/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
    • C07D233/78—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Claims (6)

PATENTKRAV 1. Forfarande for framstallning av en 1,5-disubstituerad hy- dantoinanalog, coin bar en inhiberande effekt pa blodplattsaggregation och sot, har formeln (I); 0 med ett reaktivt esterderivat av en alkohol med formeln L3,0H, dar L Sr vate,eller alkyl, L1 Sr vate eller 21, L2 Sr vdte eller Z2 och L3 ar alkyl, 21 eller 22, forutsatt att en av L, L1, L2 Sr vate och L3 inte bar samma varde sort L, Li eller LF, varvid.i definitionerna av Ll, L2 och L3 vardera as zi och 22 bar sawn betydelser coin i formeln (I); eller can reducerar en fOrening med rmeln (21) 0 Z-N •(I) van i Z Sr en vateatom eller alkyl; en av 21 och 22 betecknar gruppen -CH 2-X-X1-X2; dar X Sr fenylen, -Cf:C-, cis- eller trans-CH=CHeller -CH2-0O2-, i mitten vardera Q oberoende av den andra vales bland mate och alkyl eller bildar bAda 0 tillsammans en alkylengrupp med 4, 5 eller 6 kolatomer; X1 Sr en kovalent bindning eller en rat eller grenad alkylenkedja med 1-6 kolatomer, eventuellt med en av sina metylengrupper ersatta med oxa (-0-), fdrutsatt att minst en kolatom skiljer"uppen frAn, -CH=CH- eller -CO-grupp; L 0 vans L Sr samma som definierays 1 formeln (X), och antingen 23 Sr 1-1-Cff 2-y1-Y2-Y3 och 24 Sr -CH ,-X-X1-X2, eller Z3 Sr (=CH-X-X1-X2 och 24 Sr x dar var och en av R, IC-X2 och Y-73 Sr samma corn definierats I formeln (I), med ett lampligt reduktionsmedel, eller oar X2 Sr hydroximetyl, reducerar man en motsvarande syraester, syrahalogenid, syraanhydrid eller aldehyd med ett lampligt reduktionsmedel; och eventuellt att man omvandlar den sAlunda ester darav. erhallna fOrenen med forme'` till ett salt e//er en och X2 In vald bland 5-tetraxolyl, karboxi, karbamoyl, hydroximetyl och alkoxikarbonyl; och den andra av Z1 och Z2 betecknar gruppen * -Y3 dEr Y Sr -CR2-02-, i vilken vardera R Sr obereonde av den andra vald bland vate och metyl; Y1 Sr karbonyl, metylen, metylen substituerad med hydroxi eller metylen substituerad med hydroxi och alkyl; Y2 an en kovalent bindning eller rat eller grenad alkylenkedja med 1-7 kolatomer; eventuellt substituerad vid }colatomen intill Yi med en eller tve grupper sem oberoende av varandra valts bland alkyl, cykloalkyl, bicykloalkyl; Y3 an vate, hydroxi, alkoxi med 1-7 kolatomer, cykloalkyl, bicykloalkyl, fenyl, bensyl, fenoxi eller benSyloxi, dEr var och en av fenyl, bensyl, fenoxi och bensyloxi tan vara substituerade i bensenringen mod en eller Clara grupper valda bland hydroxi, halogen, nitro, alkoxi, fenyl och alkyl son sjS1v tan vara substituerad med en eller flera halogenatomer; eller I Sr en bindning, -CH-, eller -02-C1{2- och Yl. Y2 samt Y3 bildar tillsammans med en cykloalkylgrupp corn Sr substi- tuerad med en hydroxigrupp; fdrutsatt att nar Z Sr \rate, da gEller att
1. X Sr -C=C-, trans -CS=CH- eller -c112-c42-, dEr minst den ena Q Sr alkyl eller bildar bade Q tillsammans en alkylengrupp med 4, 5 eller 6 kolatomer; och/eller
2. X2 Sr karbamoyl eller hydroximetyl; och/eller
3. Y ar -CR2-C32-, dar Atminstone den ena R Sr metyl; och/eller
4. Y2 ar en rat eller grenad alkylen med 1-7 kolatomer, substituerad vid kolatomen intill Y1 med en eller flera grupper corn oberoende av varandra valts bland cykloalkyl och bicykloalkyl; och/eller
5. Y3 Sr cykloalkyl (nar Y2 Sr annat an en bindning), bicykloalkyl eller fenyl corn eventuellt kan vara substituerad med en eller flera grupper valda bland hydroxi, halogen, nitro, alkoxi, fenyl och alkyl corn sjalv tan vara substituerad med en eller flera halogenatomer; och/eller
6. Y Sr en bindning, -CH2-, eller -C112CH2- och Y1, Y2 saint 23 bildar tAllsammans en cykloalkylgrupp som ar substituerad med en hydroxigrupp; och salter ddrav,kEnnetecknatdErav, att (a)man cykliserar en fdrening med formeln
SE8203161A 1976-06-03 1982-05-19 Sett att framstella 1,5-disubstituerade hydantoinanaloger SE8203161L (sv)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2287776 1976-06-03
GB5034076 1976-12-02
GB1214577 1977-03-23

Publications (1)

Publication Number Publication Date
SE8203161L true SE8203161L (sv) 1982-05-19

Family

ID=27256793

Family Applications (2)

Application Number Title Priority Date Filing Date
SE7706428A SE446336B (sv) 1976-06-03 1977-06-02 Sett att framstella en 1,5-disubstituerad hydantoin, som har inhiberande effekt pa blodplettsaggregation
SE8203161A SE8203161L (sv) 1976-06-03 1982-05-19 Sett att framstella 1,5-disubstituerade hydantoinanaloger

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SE7706428A SE446336B (sv) 1976-06-03 1977-06-02 Sett att framstella en 1,5-disubstituerad hydantoin, som har inhiberande effekt pa blodplettsaggregation

Country Status (12)

Country Link
JP (1) JPS52151168A (sv)
CA (1) CA1176261A (sv)
CH (3) CH645631A5 (sv)
DE (1) DE2724948A1 (sv)
DK (1) DK244577A (sv)
ES (5) ES459412A1 (sv)
FI (1) FI71930C (sv)
FR (1) FR2362839A1 (sv)
HU (1) HU183046B (sv)
NL (1) NL7706064A (sv)
NZ (1) NZ184281A (sv)
SE (2) SE446336B (sv)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1602188A (en) * 1977-12-01 1981-11-11 Wellcome Found Hydantoin derivatives
AU527959B2 (en) * 1977-09-05 1983-03-31 Wellcome Foundation Limited, The Hydantoin derivatives
DK543178A (da) * 1977-12-01 1979-06-02 Wellcome Found Thiodydantoinderivater
DE2963795D1 (en) * 1978-01-23 1982-11-11 Beecham Group Plc Hydantoins and thiohydantoins, method for their preparation and pharmaceutical compositions containing them
EP0004723A1 (en) * 1978-03-30 1979-10-17 Beecham Group Plc Deoxyhydantoins, processes for their preparation and pharmaceutical compositions containing them
GB1599740A (en) * 1978-05-31 1981-10-07 Wellcome Found Hydantoin derivatives
AU4778279A (en) * 1978-06-15 1979-12-20 Beecham Group Limited Prostaglandin analogues
IL57504A0 (en) * 1978-06-15 1979-10-31 Beecham Group Ltd Prostagandin analogues,their preparation and pharmaceutical compositions containing
EP0006352A1 (en) * 1978-06-15 1980-01-09 Beecham Group Plc Hydantoins and thiohydantoins, process for their preparation and pharmaceutical compositions containing them
EP0007180B1 (en) * 1978-06-15 1983-03-30 Beecham Group Plc Prostaglandin analogue triazole derivatives, processes for their preparation and a pharmaceutical composition containing them
IL59065A0 (en) * 1979-01-18 1980-05-30 Beecham Group Ltd Hydantoin derivatives,their preparation pharmaceutical compositons containing them
JPS55151569A (en) * 1979-05-09 1980-11-26 Wellcome Found Optically active heterocyclic compounds* their synthesis and medical blend containing them
US4684735A (en) * 1985-07-01 1987-08-04 Stauffer Chemical Company Promotion of raney nickel hydrogenation catalyst
JP3022878U (ja) * 1995-08-18 1996-04-02 有限会社春江加工 ミニディスク用ケース
MXPA04005123A (es) * 2001-11-30 2005-02-17 Lilly Co Eli Agonistas del receptor activado por proliferador de peroxisoma.
CA2528179C (en) * 2003-06-06 2013-10-22 Allergan, Inc. Piperidinyl prostaglandin e analogs
US7179820B2 (en) * 2003-06-06 2007-02-20 Allergan, Inc. Piperidinyl prostaglandin E analogs

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1524818A (en) * 1974-11-29 1978-09-13 Beecham Group Ltd 12-azaprostaglandins

Also Published As

Publication number Publication date
ES459412A1 (es) 1978-11-01
FI71930C (sv) 1987-03-09
ES8103057A1 (es) 1981-02-16
ES489883A0 (es) 1981-02-16
CH646426A5 (en) 1984-11-30
NL7706064A (nl) 1977-12-06
HU183046B (en) 1984-04-28
SE7706428L (sv) 1977-12-04
ES470428A1 (es) 1979-09-01
FR2362839B1 (sv) 1980-02-01
DK244577A (da) 1977-12-04
DE2724948A1 (de) 1977-12-15
CA1176261A (en) 1984-10-16
CH645631A5 (en) 1984-10-15
JPS52151168A (en) 1977-12-15
NZ184281A (en) 1980-04-28
FR2362839A1 (fr) 1978-03-24
SE446336B (sv) 1986-09-01
ES478156A1 (es) 1979-11-01
JPS6222986B2 (sv) 1987-05-20
FI71930B (fi) 1986-11-28
FI771763A (fi) 1977-12-04
CH647511A5 (en) 1985-01-31
ES482010A1 (es) 1980-08-16

Similar Documents

Publication Publication Date Title
SE8203161L (sv) Sett att framstella 1,5-disubstituerade hydantoinanaloger
DE3270307D1 (en) Succinimide derivates and process for preparation thereof
GB1515414A (en) 2 descarboxy-2-(tetrazol-5-yl)-11-desoxy-15-substituted-omega-pentanorprostaglandins
SE8008334L (sv) Analogiforfarande for framstellning av 16-fenoxi- och 16-(o, m eller p)-substituerade fenoxiprosta-4,5,13-triensyraderivat
SE8205870L (sv) Nya produkter 3-amino-2-oxo-azetidin-1-sulfonsyraderivat, sett for framstellning derav, anvendning derav som lekemedel, kompositioner innehallande dem och erhallna nya mellanprodukter
IE790652L (en) Imidazole derivatives
IE34511L (en) Piperazine ethers.
WO1999030722A8 (en) Pharmaceutical compositions for mucolysis and treatment of inflammation
PL125506B1 (en) Process for preparing novel inhibitors of dipeptidase
HUP0104942A2 (hu) Policiklusos tiazolidin-2-ilidén-aminok, eljárás a vegyületek előállítására és gyógyszerként történő alkalmazásuk
KR890005046A (ko) 알카디엔 유도체, 이들의 제조방법 및 이를 함유하는 제약학적 조성물
IE830142L (en) 2-(phenoxyalkyl)-imidazoles
ES496446A0 (es) Un metodo para la preparacion de derivados del acido prope- noico.
GR80832B (en) Cyclic ethers
GB1291644A (en) Substituted 1-indancarboxylic acids, their esters and salts
JPS5531022A (en) Hydroxamic acid derivative and its preparation
US4430340A (en) Stabilization of PGI2 compounds with surfactants
GB1290145A (sv)
ES8504149A1 (es) Procedimiento de obtencion de aductos aldolicos de efectos fungicidas y herbicidas
GB1508168A (en) 11-deoxy-15-substituted-16,17,18,19,20-pentanorprostaglandins
IE36517L (en) Isothiazolyl-alkyl guanidines.
RU94019325A (ru) Фунгицидный состав
JPS5661360A (en) 1-substituted imidazole derivative and its preparation
ES8506192A1 (es) Un metodo de producir extractos que contienen alergeno
HUT62195A (en) Process for producing weight increasing agents and fodder comprising thiobenzoyl morpholide derivatives

Legal Events

Date Code Title Description
NAV Patent application has lapsed

Ref document number: 8203161-8